NKAPD1

Across TCGA pan-cancer cohorts, NKAPD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NKAPD1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NKAPD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NKAPD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where NKAPD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.963	0.543	<.001	61	view →
CCRCC	DFS	Quartile	II,III,IV	0.798	1.000	.014	8	view →
PDAC	DFS	Median	III,IV	1.000	0.607	.003	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.907	.023	2	view →
HNSC	DFS	Median	III,IV	0.494	0.732	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NKAPD1–LUAD (OS)

Open the LUAD breakdown →